Immunotherapy with immune checkpoint inhibitors (ICIs) has become the backbone of treatment for non-small-cell lung cancer (NSCLC), particularly in patients with high programmed death ligand 1 (PD-L1) expression. Here, CD274 is linked to non-small cell lung carcinoma.